Peringatan Keamanan

Symptoms of overdose include confusion, coma, impaired coordination, sleepiness, and slowed reaction time.

Flunitrazepam

DB01544

small molecule approved illicit

Deskripsi

Flunitrazepam is a benzodiazepine with pharmacologic actions similar to those of diazepam that can cause anterograde amnesia. Some reports indicate that it is used as a date rape drug and suggest that it may precipitate violent behavior. The United States Government has banned the importation of this drug.

Struktur Molekul 2D

Berat 313.2832
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) 18-26 hours
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

50% (suppository) and 64-77% (oral)

Metabolisme

Hepatic.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Makanan

4 Data
  • 1. Avoid alcohol.
  • 2. Avoid grapefruit products.
  • 3. Limit caffeine intake.
  • 4. Take with food.

Interaksi Obat

1127 Data
Buprenorphine Flunitrazepam may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
Doxylamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Flunitrazepam.
Dronabinol Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Flunitrazepam.
Droperidol Droperidol may increase the central nervous system depressant (CNS depressant) activities of Flunitrazepam.
Hydrocodone Flunitrazepam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
Hydroxyzine Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Flunitrazepam.
Magnesium sulfate The therapeutic efficacy of Flunitrazepam can be increased when used in combination with Magnesium sulfate.
Methotrimeprazine Flunitrazepam may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.
Metyrosine Flunitrazepam may increase the sedative activities of Metyrosine.
Minocycline Minocycline may increase the central nervous system depressant (CNS depressant) activities of Flunitrazepam.
Mirtazapine Flunitrazepam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
Nabilone Nabilone may increase the central nervous system depressant (CNS depressant) activities of Flunitrazepam.
Orphenadrine Flunitrazepam may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
Paraldehyde Flunitrazepam may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
Perampanel Perampanel may increase the central nervous system depressant (CNS depressant) activities of Flunitrazepam.
Pramipexole Flunitrazepam may increase the sedative activities of Pramipexole.
Ropinirole Flunitrazepam may increase the sedative activities of Ropinirole.
Rotigotine Flunitrazepam may increase the sedative activities of Rotigotine.
Rufinamide The risk or severity of adverse effects can be increased when Rufinamide is combined with Flunitrazepam.
Suvorexant Flunitrazepam may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
Tapentadol Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Flunitrazepam.
Thalidomide Flunitrazepam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
Zolpidem Flunitrazepam may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
Clozapine The risk or severity of adverse effects can be increased when Flunitrazepam is combined with Clozapine.
Methadone Flunitrazepam may increase the central nervous system depressant (CNS depressant) activities of Methadone.
Sodium oxybate Flunitrazepam may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.
Teduglutide The serum concentration of Flunitrazepam can be increased when it is combined with Teduglutide.
Yohimbine The therapeutic efficacy of Flunitrazepam can be increased when used in combination with Yohimbine.
Irinotecan The risk or severity of neutropenia can be increased when Flunitrazepam is combined with Irinotecan.
Flumazenil Flumazenil may decrease the sedative activities of Flunitrazepam.
Ethanol Flunitrazepam may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
Azelastine Flunitrazepam may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
Brimonidine Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Flunitrazepam.
Zimelidine The risk or severity of adverse effects can be increased when Flunitrazepam is combined with Zimelidine.
Dapoxetine The risk or severity of adverse effects can be increased when Flunitrazepam is combined with Dapoxetine.
Seproxetine The risk or severity of adverse effects can be increased when Flunitrazepam is combined with Seproxetine.
Fluvoxamine The risk or severity of adverse effects can be increased when Flunitrazepam is combined with Fluvoxamine.
Citalopram The risk or severity of adverse effects can be increased when Flunitrazepam is combined with Citalopram.
Duloxetine The risk or severity of adverse effects can be increased when Flunitrazepam is combined with Duloxetine.
Trazodone The risk or severity of adverse effects can be increased when Flunitrazepam is combined with Trazodone.
Paroxetine The risk or severity of adverse effects can be increased when Flunitrazepam is combined with Paroxetine.
Sibutramine The risk or severity of adverse effects can be increased when Flunitrazepam is combined with Sibutramine.
Escitalopram The risk or severity of adverse effects can be increased when Flunitrazepam is combined with Escitalopram.
Milnacipran The risk or severity of adverse effects can be increased when Flunitrazepam is combined with Milnacipran.
Desvenlafaxine The risk or severity of adverse effects can be increased when Flunitrazepam is combined with Desvenlafaxine.
Levomilnacipran The risk or severity of adverse effects can be increased when Flunitrazepam is combined with Levomilnacipran.
Indalpine The risk or severity of adverse effects can be increased when Flunitrazepam is combined with Indalpine.
Ritanserin The risk or severity of adverse effects can be increased when Flunitrazepam is combined with Ritanserin.
Alaproclate The risk or severity of adverse effects can be increased when Flunitrazepam is combined with Alaproclate.
Cyproheptadine The risk or severity of CNS depression can be increased when Cyproheptadine is combined with Flunitrazepam.
Propiomazine The risk or severity of CNS depression can be increased when Propiomazine is combined with Flunitrazepam.
Tolterodine The metabolism of Flunitrazepam can be decreased when combined with Tolterodine.
Nortriptyline The risk or severity of CNS depression can be increased when Nortriptyline is combined with Flunitrazepam.
Doxepin The risk or severity of CNS depression can be increased when Doxepin is combined with Flunitrazepam.
Imipramine The risk or severity of CNS depression can be increased when Imipramine is combined with Flunitrazepam.
Desipramine The risk or severity of CNS depression can be increased when Desipramine is combined with Flunitrazepam.
Olanzapine The risk or severity of CNS depression can be increased when Olanzapine is combined with Flunitrazepam.
Quinidine The metabolism of Flunitrazepam can be decreased when combined with Quinidine.
Zopiclone The risk or severity of adverse effects can be increased when Flunitrazepam is combined with Zopiclone.
Caffeine The therapeutic efficacy of Flunitrazepam can be decreased when used in combination with Caffeine.
Dyphylline The therapeutic efficacy of Flunitrazepam can be decreased when used in combination with Dyphylline.
Pentoxifylline The therapeutic efficacy of Flunitrazepam can be decreased when used in combination with Pentoxifylline.
Mercaptopurine The therapeutic efficacy of Flunitrazepam can be decreased when used in combination with Mercaptopurine.
Oxtriphylline The therapeutic efficacy of Flunitrazepam can be decreased when used in combination with Oxtriphylline.
Theobromine The therapeutic efficacy of Flunitrazepam can be decreased when used in combination with Theobromine.
Fenethylline The therapeutic efficacy of Flunitrazepam can be decreased when used in combination with Fenethylline.
8-azaguanine The therapeutic efficacy of Flunitrazepam can be decreased when used in combination with 8-azaguanine.
7,9-Dimethylguanine The therapeutic efficacy of Flunitrazepam can be decreased when used in combination with 7,9-Dimethylguanine.
Xanthine The therapeutic efficacy of Flunitrazepam can be decreased when used in combination with Xanthine.
7-Deazaguanine The therapeutic efficacy of Flunitrazepam can be decreased when used in combination with 7-Deazaguanine.
Guanine The therapeutic efficacy of Flunitrazepam can be decreased when used in combination with Guanine.
9-Methylguanine The therapeutic efficacy of Flunitrazepam can be decreased when used in combination with 9-Methylguanine.
Peldesine The therapeutic efficacy of Flunitrazepam can be decreased when used in combination with Peldesine.
Hypoxanthine The therapeutic efficacy of Flunitrazepam can be decreased when used in combination with Hypoxanthine.
9-Deazaguanine The therapeutic efficacy of Flunitrazepam can be decreased when used in combination with 9-Deazaguanine.
Propentofylline The therapeutic efficacy of Flunitrazepam can be decreased when used in combination with Propentofylline.
Valomaciclovir The therapeutic efficacy of Flunitrazepam can be decreased when used in combination with Valomaciclovir.
3-isobutyl-1-methyl-7H-xanthine The therapeutic efficacy of Flunitrazepam can be decreased when used in combination with 3-isobutyl-1-methyl-7H-xanthine.
Uric acid The therapeutic efficacy of Flunitrazepam can be decreased when used in combination with Uric acid.
Doxofylline The therapeutic efficacy of Flunitrazepam can be decreased when used in combination with Doxofylline.
6-O-benzylguanine The therapeutic efficacy of Flunitrazepam can be decreased when used in combination with 6-O-benzylguanine.
Lisofylline The therapeutic efficacy of Flunitrazepam can be decreased when used in combination with Lisofylline.
Lobucavir The therapeutic efficacy of Flunitrazepam can be decreased when used in combination with Lobucavir.
Cafedrine The therapeutic efficacy of Flunitrazepam can be decreased when used in combination with Cafedrine.
Theodrenaline The therapeutic efficacy of Flunitrazepam can be decreased when used in combination with Theodrenaline.
Bamifylline The therapeutic efficacy of Flunitrazepam can be decreased when used in combination with Bamifylline.
Proxyphylline The therapeutic efficacy of Flunitrazepam can be decreased when used in combination with Proxyphylline.
Acefylline The therapeutic efficacy of Flunitrazepam can be decreased when used in combination with Acefylline.
Etamiphylline The therapeutic efficacy of Flunitrazepam can be decreased when used in combination with Etamiphylline.
Pentifylline The therapeutic efficacy of Flunitrazepam can be decreased when used in combination with Pentifylline.
Bufylline The therapeutic efficacy of Flunitrazepam can be decreased when used in combination with Bufylline.
Bromotheophylline The therapeutic efficacy of Flunitrazepam can be decreased when used in combination with Bromotheophylline.
Furafylline The therapeutic efficacy of Flunitrazepam can be decreased when used in combination with Furafylline.
8-chlorotheophylline The therapeutic efficacy of Flunitrazepam can be decreased when used in combination with 8-chlorotheophylline.
PCS-499 The therapeutic efficacy of Flunitrazepam can be decreased when used in combination with PCS-499.
Botulinum toxin type B The risk or severity of CNS depression can be increased when Botulinum toxin type B is combined with Flunitrazepam.
Botulinum toxin type A The risk or severity of CNS depression can be increased when Botulinum toxin type A is combined with Flunitrazepam.
Baclofen Baclofen may increase the central nervous system depressant (CNS depressant) activities of Flunitrazepam.
Ethchlorvynol The risk or severity of CNS depression can be increased when Ethchlorvynol is combined with Flunitrazepam.
Succinylcholine The risk or severity of CNS depression can be increased when Succinylcholine is combined with Flunitrazepam.

Target Protein

Translocator protein TSPO
GABA(A) Receptor GABRA1
GABA(A) Receptor Benzodiazepine Binding Site GABRA1

Referensi & Sumber

Synthesis reference: Kariss, J. and Newmark, H.L.; U.S. Patent 3,116,203; December 31, 1963; assigned to Hoffmann-la Roche Inc.? Kariss, J. and Newmark, H.L.; US. Patent 3,123,529; March 3,1964; assigned to Hoffmann-La Roche Inc. ?Keiler, O., Steiger, N. and Sternbach, L.H.; U.S. Patent 3,203,990; August 31, 1965; assigned to Hoffmann-La Roche Inc.
Artikel (PubMed)
  • PMID: 2883820
    Rickels K: The clinical use of hypnotics: indications for use and the need for a variety of hypnotics. Acta Psychiatr Scand Suppl. 1986;332:132-41.
  • PMID: 7782744
    Robertson MD, Drummer OH: Postmortem drug metabolism by bacteria. J Forensic Sci. 1995 May;40(3):382-6.
  • PMID: 2570451
    Oelschlager H: Chemical and pharmacologic aspects of benzodiazepines. Schweiz Rundsch Med Prax. 1989 Jul 4;78(27-28):766-72.
  • PMID: 11995921
    Usami N, Yamamoto T, Shintani S, Ishikura S, Higaki Y, Katagiri Y, Hara A: Substrate specificity of human 3(20)alpha-hydroxysteroid dehydrogenase for neurosteroids and its inhibition by benzodiazepines. Biol Pharm Bull. 2002 Apr;25(4):441-5.
  • PMID: 17287588
    Tokunaga S, Takeda Y, Shinomiya K, Hirase M, Kamei C: Effects of some H1-antagonists on the sleep-wake cycle in sleep-disturbed rats. J Pharmacol Sci. 2007 Feb;103(2):201-6. Epub 2007 Feb 8.

Contoh Produk & Brand

Produk: 0 • International brands: 5
International Brands
  • Hipnosedon — Roche
  • Hypnodorm — Alphapharm
  • Narcozep — Roche
  • Rohypnol — Roche
  • Roipnol — Roche

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul